Drug Trial Radar · NCT01127451
Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma
Last checked: Nov 20, 2026Latest source record: Apr 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
Jun 22, 2010
Primary completion
Apr 7, 2015
Study completion Apr 7, 2015
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- PharmaBio Development Inc.
- First posted
- May 20, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether participants with Stage IIIC and Stage IV Melanoma experience benefit when treated with Denileukin diftitox in two different dosing schedules.
Conditions
- Stage IIIC Melanoma
- Stage IV Melanoma
Interventions
Denileukin diftitoxDrug
Denileukin diftitox intravenous infusion over 30-60 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Immune-related Overall Response Rate (irORR)Time frame: From the start of treatment up to 1 year 6 months
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Encinitas, California
Site not named
Los Angeles, California
Site not named
Washington D.C., District of Columbia
Site not named
Chicago, Illinois
Site not named
Louisville, Kentucky
Site not named
Baltimore, Maryland
Site not named
Detroit, Michigan
Site not named
Lincoln, Nebraska
Site not named
Portland, Oregon
Site not named
Amarillo, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.